Jazz Pharmaceuticals (NASDAQ:JAZZ) has been given an average recommendation of “Buy” by the twenty-four analysts that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $181.52.
Several analysts have weighed in on the stock. HC Wainwright reissued a “neutral” rating and issued a $160.00 price target (up from $150.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 23rd. Leerink Swann began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $180.00 price objective on the stock. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 13th. B. Riley restated a “buy” rating and issued a $206.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 16th. Finally, Deutsche Bank set a $170.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 16th.
Jazz Pharmaceuticals stock opened at $157.95 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $9,445.95, a price-to-earnings ratio of 18.28, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97. Jazz Pharmaceuticals has a twelve month low of $128.58 and a twelve month high of $163.75.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the consensus estimate of $2.73 by ($0.15). The business had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. equities analysts anticipate that Jazz Pharmaceuticals will post 11.48 EPS for the current fiscal year.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now owns 267,468 shares in the company, valued at $40,120,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $139.99, for a total transaction of $27,998.00. Following the transaction, the executive vice president now owns 21,469 shares in the company, valued at approximately $3,005,445.31. The disclosure for this sale can be found here. Insiders have sold 14,657 shares of company stock worth $2,189,989 in the last quarter. 4.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. HBK Investments L P increased its position in shares of Jazz Pharmaceuticals by 159.8% during the fourth quarter. HBK Investments L P now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $3,043,000 after buying an additional 13,900 shares during the period. Teachers Advisors LLC grew its holdings in Jazz Pharmaceuticals by 16.1% in the fourth quarter. Teachers Advisors LLC now owns 601,785 shares of the specialty pharmaceutical company’s stock worth $81,030,000 after purchasing an additional 83,426 shares during the period. Ellington Management Group LLC purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $633,000. Compagnie Lombard Odier SCmA purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $577,000. Finally, Franklin Resources Inc. grew its holdings in Jazz Pharmaceuticals by 11.8% in the fourth quarter. Franklin Resources Inc. now owns 378,631 shares of the specialty pharmaceutical company’s stock worth $50,983,000 after purchasing an additional 39,900 shares during the period. Institutional investors own 91.24% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/23/jazz-pharmaceuticals-jazz-receives-181-52-consensus-pt-from-brokerages.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.